Glaxosmithkline Plc And Vir Biotechnology, Inc. Entered Into Research And Development Partnership For Influenza Therapeutics Market
Growing new drug approval for the treatment of influenza is projected to foster the growth of the influenza therapeutics market. For instance, in October 2018, Roche announced that the U.S. Food and Drug Administration (FDA) approved Xofluza (TM) (baloxavir marboxil) for the treatment of acute, uncomplicated influenza or flu, in people 12 years of age and older. A rising number of clinical pipeline studies is projected to augment the growth of the market. For instance, in January 2018, Romark Laboratories L.C. initiated the phase 3 clinical trial for Nitazoxanide to evaluate its efficacy and safety in the treatment of uncomplicated influenza. In November 2018, the Henry M. Jackson Foundation for the Advancement of Military Medicine, initiated a phase 4 clinical trial study for egg-based influenza vaccines to study the realistic evaluation of influenza vaccine effectiveness in active duty members, military retirees, and other Department of Defense (DOD) beneficiaries In February 2021, ...